Posted by Michael Wonder on 07 Apr 2018
Besponsa approved by Health Canada for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
6 April 2018 - First and only CD22-directed antibody-drug conjugate indicated for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia.
Pfizer Canada announced today that Health Canada has approved Besponsa (inotuzumab ozogamicin for injection) as a monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia. Besponsa is the first and only CD22-directed antibody-drug conjugate approved for this indication.
“The approval of Besponsa adds a much needed option for relapsed or refractory adult B-cell ALL patients,” says John Leasure, Pfizer Oncology Canada Lead, Pfizer Canada Inc. “Pfizer Canada is proud to bring the first CD22-directed antibody-drug conjugate to Canadians, demonstrating our commitment to offering innovative new cancer treatments to patients in need.”
